Shares of Veradigm Inc. (NASDAQ:MDRX – Get Rating) saw unusually-high trading volume on Wednesday . Approximately 469,463 shares changed hands during trading, a decline of 62% from the previous session's volume of 1,221,541 shares.The stock last traded at $18.03 and had previously closed at $18.03.

Analyst Ratings Changes

MDRX has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their price objective on Veradigm from $19.00 to $20.00 and gave the company an "underweight" rating in a research report on Friday, November 18th. Piper Sandler reaffirmed an "overweight" rating and set a $17.00 price objective on shares of Veradigm in a research report on Friday, November 4th. The Goldman Sachs Group upgraded Veradigm from a "neutral" rating to a "buy" rating and increased their price target for the company from $22.00 to $23.00 in a research note on Tuesday, November 8th. StockNews.com assumed coverage on Veradigm in a research note on Wednesday, October 12th. They issued a "hold" rating for the company. Finally, TheStreet upgraded Veradigm from a "c+" rating to a "b-" rating in a research note on Wednesday, November 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Veradigm presently has a consensus rating of "Moderate Buy" and a consensus price target of $22.67.

Veradigm Stock Performance

The stock has a market capitalization of $1.97 billion, a PE ratio of 42.02, a PEG ratio of 1.57 and a beta of 1.01. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.17. The firm has a 50 day moving average price of $18.26 and a 200-day moving average price of $16.77.

Insider Transactions at Veradigm

In other news, CEO Richard J. Poulton sold 10,000 shares of the firm's stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $18.14, for a total value of $181,400.00. Following the completion of the transaction, the chief executive officer now directly owns 722,517 shares in the company, valued at $13,106,458.38. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director David B. Stevens sold 43,134 shares of the firm's stock in a transaction dated Tuesday, December 6th. The stock was sold at an average price of $18.47, for a total transaction of $796,684.98. Following the sale, the director now directly owns 32,384 shares of the company's stock, valued at $598,132.48. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Richard J. Poulton sold 10,000 shares of the firm's stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $18.14, for a total value of $181,400.00. Following the sale, the chief executive officer now directly owns 722,517 shares in the company, valued at $13,106,458.38. The disclosure for this sale can be found here. Insiders sold a total of 61,776 shares of company stock worth $1,137,271 over the last three months. 2.29% of the stock is currently owned by insiders.

Institutional Trading of Veradigm

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC grew its holdings in Veradigm by 578.4% during the third quarter. CWM LLC now owns 2,103 shares of the software maker's stock worth $32,000 after acquiring an additional 1,793 shares during the period. C M Bidwell & Associates Ltd. acquired a new stake in Veradigm in the third quarter valued at approximately $33,000. Robeco Institutional Asset Management B.V. acquired a new stake in Veradigm in the third quarter valued at approximately $93,000. Ritholtz Wealth Management acquired a new stake in Veradigm in the third quarter valued at approximately $158,000. Finally, MQS Management LLC acquired a new stake in Veradigm in the second quarter valued at approximately $154,000. 99.76% of the stock is owned by institutional investors and hedge funds.

About Veradigm

(Get Rating)

Allscripts Healthcare Solutions, Inc, together with its subsidiaries, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.

Read More

• Get a free copy of the StockNews.com research report on Veradigm (MDRX)
• EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
• Does Oil Services Firm NOV Have Enough Energy To Maintain Rally?
• Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
• The Future Of E-Commerce: Analysis And New Data
• Chevron Delights Shareholders with $75 Billion in Share Buybacks

Receive News & Ratings for Veradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradigm and related companies with MarketBeat.com's FREE daily email newsletter.